Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.

Greenlee ML, Laub JB, Rouen GP, DiNinno F, Hammond ML, Huber JL, Sundelof JG, Hammond GG.

Bioorg Med Chem Lett. 1999 Nov 15;9(22):3225-30.

PMID:
10576693
2.

The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.

Laub JB, Greenlee ML, DiNinno F, Huber JL, Sundelof JG.

Bioorg Med Chem Lett. 1999 Oct 18;9(20):2973-6.

PMID:
10571158
3.

Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.

Ratcliffe RW, Wilkening RR, Wildonger KJ, Waddell ST, Santorelli GM, Parker DL Jr, Morgan JD, Blizzard TA, Hammond ML, Heck JV, Huber J, Kohler J, Dorso KL, St Rose E, Sundelof JG, May WJ, Hammond GG.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):679-84.

PMID:
10201828
4.

Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenem antibiotic.

Rosen H, Hajdu R, Silver L, Kropp H, Dorso K, Kohler J, Sundelof JG, Huber J, Hammond GG, Jackson JJ, Gill CJ, Thompson R, Pelak BA, Epstein-Toney JH, Lankas G, Wilkening RR, Wildonger KJ, Blizzard TA, DiNinno FP, Ratcliffe RW, Heck JV, Kozarich JW, Hammond ML.

Science. 1999 Jan 29;283(5402):703-6.

5.

In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).

Gill CJ, Jackson JJ, Gerckens LS, Pelak BA, Thompson RK, Sundelof JG, Kropp H, Rosen H.

Antimicrob Agents Chemother. 1998 Aug;42(8):1996-2001.

6.

Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase.

Toney JH, Fitzgerald PM, Grover-Sharma N, Olson SH, May WJ, Sundelof JG, Vanderwall DE, Cleary KA, Grant SK, Wu JK, Kozarich JW, Pompliano DL, Hammond GG.

Chem Biol. 1998 Apr;5(4):185-96.

7.

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H.

Antimicrob Agents Chemother. 1997 Nov;41(11):2339-44.

8.

Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Sundelof JG, Hajdu R, Gill CJ, Thompson R, Rosen H, Kropp H.

Antimicrob Agents Chemother. 1997 Aug;41(8):1743-8.

9.

Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus.

Sundelof JG, Thompson R, White KM, Sasor MW, Cama L, Kropp H.

Antimicrob Agents Chemother. 1996 Mar;40(3):795-8.

10.

Pharmacokinetics of L-671,329 in rhesus monkeys and DBA/2 mice.

Sundelof JG, Hajdu R, Cleare WJ, Onishi J, Kropp H.

Antimicrob Agents Chemother. 1992 Mar;36(3):607-10.

11.

Antibacterial activity of imipenem: the first thienamycin antibiotic.

Kropp H, Gerckens L, Sundelof JG, Kahan FM.

Rev Infect Dis. 1985 Jul-Aug;7 Suppl 3:S389-410. Review.

PMID:
3931196
12.

Thienamycin: development of imipenen-cilastatin.

Kahan FM, Kropp H, Sundelof JG, Birnbaum J.

J Antimicrob Chemother. 1983 Dec;12 Suppl D:1-35. Review.

PMID:
6365872
13.

Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.

Norrby SR, Alestig K, Björnegård B, Burman LA, Ferber F, Huber JL, Jones KH, Kahan FM, Kahan JS, Kropp H, Meisinger MA, Sundelof JG.

Antimicrob Agents Chemother. 1983 Feb;23(2):300-7.

14.

Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Kropp H, Sundelof JG, Hajdu R, Kahan FM.

Antimicrob Agents Chemother. 1982 Jul;22(1):62-70.

15.

MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Kropp H, Sundelof JG, Kahan JS, Kahan FM, Birnbaum J.

Antimicrob Agents Chemother. 1980 Jun;17(6):993-1000.

Supplemental Content

Loading ...
Support Center